ClinicalTrials.Veeva

Menu

Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia

C

Center for Epidemiology and Health Research, Germany

Status

Completed

Conditions

Contraception

Study type

Observational

Funder types

Other

Identifiers

NCT01319500
ZEG 2009_02

Details and patient eligibility

About

This study investigates the drug utilization pattern of Oral Contraceptives (OC) in Croatia. Gynecologists and Dermatologists were asked to contribute OC prescribing data to this study.

Full description

Large, prospective non-interventional cohort studies with active surveillance of study participants indicate that many users of oral contraceptives use these preparations not only for contraception but also for the treatment of hormone-dependent diseases and symptoms - such as premenstrual dysphoric disorder, acne, endometriosis, ovarian cysts, polycystic ovary syndrome, bleeding disorders and painful periods. In the International Active Surveillance Study of Women Taking Oral Contraceptives (INAS) more than 30% of participants reported that they use their OC for contra¬ception as well as for the treatment of one of the mentioned conditions.

It is also conceivable that some women use OC not for contraception but only for one of these hormone-dependent conditions. In most instances the exclusive use for these conditions would constitute off-label use as only few preparations have a stand-alone approved indication for one of these conditions.

For many countries the actual extent of off-label use of OCs for these conditions is unknown. This applies also to Croatia. Therefore, the Croatian health authority requested a drug utilization study to investigate current prescribing indications for Yasmin® and other OCs in Croatia. The study details were agreed upon with the Croatian health authority.

Enrollment

3,776 patients

Sex

Female

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • women with an OC prescription during the timeframe (Feb-March 2011)

Trial design

3,776 participants in 2 patient groups

Yasmin
Description:
Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC "Yasmin"
Other OCs
Description:
Users of OCs except Yasmin ("Other OCs")

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems